Alcohol consumption has serious potential consequences for persons with type 1 diabetes (T1D). This study examined associations between alcohol consumption status and diabetes outcomes. Participants were N=933 adults at Type 1 Diabetes Exchange Registry clinics who completed an emailed set of standardized self-report instruments that included items on alcohol use; A1c values were extracted from charts and reported by clinics. Participants were on average (SD) age 38 (16) years, 61% female, and 90% non-Hispanic white, and mean (SD) A1c was 7.8% (1.5%). The sample was 61% (n = 567) current non-binge drinkers, 19% (n = 174) current binge drinkers, 11% (n = 103) had never consumed alcohol, and 9% (n = 89) former drinkers. After controlling for relevant covariates, there was a trend toward higher diabetes self-care scores in never drinkers compared to current non-binge drinkers, current binge drinkers, and former drinkers, and a trend towards lower diabetes distress scores relative to current non-binge drinkers and former drinkers. The odds of a history of severe hypoglycemia, and odds of a neuropathy diagnosis, were lower among never drinkers relative to former drinkers (adjusted p < .04). Never drinkers did not differ from other drinking status groups on frequency of self-monitoring blood glucose, A1c, history of diabetic ketoacidosis, or nephropathy diagnosis (adjusted p’s≤.01). BMI was higher among never drinkers compared to former drinkers and non-binge drinkers (adjusted p > .05). These results suggest that experiencing severe hypoglycemia and being diagnosed with neuropathy may motivate some drinkers to stop drinking, and that never drinkers have more salutary self-care and distress, but higher BMI. Strategies to help patients with T1D manage alcohol are warranted.

Disclosure

S.M. Alessi: None. N.C. Foster: None. C. Rash: None. M.A. Van Name: Research Support; Self; Novo Nordisk Inc. W.V. Tamborlane: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic MiniMed, Inc., Novo Nordisk Inc., Sanofi, Takeda Pharmaceutical Company Limited. J. Wagner: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.